Search the Newsreel

LifeMD (LFMD) Results Breakdown: Profit Per Share Falls Below Its Benchmark in the Latest Session; Closing Reaction

LifeMD (LFMD) Results Review: The Bottom-Line Figure Trails Its Comparison under the Current Snapshot; Trading Move: The Stock Records a 3.98% Increase - Tech Earnings Analysis

LifeMD (LFMDP) Results at a Glance: EPS Falls Short of Its Estimate in Latest Trading; Post-Earnings Trading: The Market Price Moves 0.65% Higher in the Latest Session - Forward EPS Estimate

LifeMD (NASDAQ: LFMD) insider reports stock trade

LifeMD, Inc. (NASDAQ: LFMD) Director Joan LaRovere reported an insider stock transaction, acquiring 35,000 shares of common stock through a grant/award on August 11, 2026. These restricted shares will vest on June 1, 2027, bringing LaRovere's direct holdings to 142,050 shares. The filing of …

(LFMDP) as a Liquidity Pulse for Institutional Tactics

This article provides an AI-generated analysis of LifeMD Inc. 8.875% Series A Cumulative Perpetual Preferred Stock (NASDAQ: LFMDP), indicating a neutral sentiment and a mid-channel oscillation pattern. It outlines three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss …

Russell Investments Group Ltd. Buys 309,436 Shares of LifeMD, Inc. $LFMD

Russell Investments Group Ltd. significantly increased its stake in LifeMD, Inc. by 5,801.2% in the second quarter, acquiring 309,436 additional shares and now owning 314,770 shares valued at approximately $1.3 million. This increase occurred despite LifeMD missing its latest quarterly earnings and revenue estimates. …

Walleye Capital LLC Purchases New Stake in LifeMD, Inc. $LFMD

Walleye Capital LLC has acquired a new stake of 323,898 shares in LifeMD, Inc. (NASDAQ:LFMD) during the second quarter, valued at approximately $1.34 million, giving them a 0.67% ownership. This comes as institutional investors now collectively own 35.52% of the telehealth company. Despite LifeMD …

HC Wainwright Analysts Boost Earnings Estimates for LifeMD

HC Wainwright analysts have increased their Q4 2027 earnings per share forecast for LifeMD to $0.17 from $0.15, while maintaining a "Buy" rating and a $9 price target. Despite this, analyst sentiment remains mixed with a "Moderate Buy" consensus rating but several recent downgrades. …

LifeMD, Inc. (NASDAQ:LFMD) Given Consensus Recommendation of "Moderate Buy" by Brokerages

LifeMD, Inc. (NASDAQ:LFMD) has received a "Moderate Buy" consensus rating from ten brokerages, with an average 12-month price target of $7.57. Despite this, the company reported a slight miss on quarterly earnings and revenue expectations, posting a loss of $0.16 per share and $47.28 …

LifeMD, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:LFMD) 2026-08-11

LifeMD, Inc. published its Q2 2026 earnings call presentation, reporting an EPS of -$0.15, missing estimates by $0.10, and revenue of $47.28M, down 24.01% year-over-year and missing estimates by $1.82M. The presentation is provided for investors to review the company's financial performance.

Renaissance Technologies LLC Trims Stock Holdings in LifeMD, Inc. $LFMD

Renaissance Technologies LLC reduced its stake in LifeMD, Inc. by 25.4% in the first quarter, selling 380,000 shares and retaining over 1.1 million shares. Despite this, analysts generally hold a "Moderate Buy" consensus for LifeMD, with an average price target of $7.57, though some …

LifeMD (NASDAQ:LFMD) Price Target Lowered to $9.00 at HC Wainwright

HC Wainwright has lowered its price target for LifeMD (NASDAQ:LFMD) to $9.00 from $10.00 but maintained a "buy" rating, indicating a potential upside of 164.71%. The revision follows LifeMD's recent quarterly results, which missed analyst expectations with a reported loss of $0.16 per share …

LifeMD, Inc. Stock 12‑Month Price Target Cut to $9, Implies 145% Upside

LifeMD, Inc.'s average 12-month price target has been reduced from $9.88 to $9 by 8 analysts, with forecasts ranging from $7 to $15 per share. Despite the cut, this new target still suggests a substantial 145% potential upside from its Aug. 5 closing price. …

LifeMD Inc reports results for the quarter ended June 30 - Earnings Summary

LifeMD Inc has released its earnings summary for the quarter that ended on June 30. The article, sourced from Reuters, provides a brief announcement of these financial results. To access the full details, readers are directed to the complete article available on TradingView.

LifeMD, Inc. Q2 2026: Revenue $47.28M, EPS $(0.16) — 10-Q Summary

LifeMD, Inc. reported its second-quarter 2026 results, showing a revenue of $47.28 million, a 3.6% decrease year-over-year, and a net loss of $7.86 million, significantly wider than the previous year's loss. The diluted loss per share was $(0.16). Despite a decline in online product …

B. Riley Adjusts Price Target on LifeMD to $8 From $10, Maintains Buy Rating

LifeMD, Inc. Q2 2026 Earnings Call Summary

(LFMDP) Risk Channels and Responsive Allocation

This article provides an AI-driven analysis of LifeMD Inc. 8.875% Series A Cumulative Perpetual Preferred Stock (NASDAQ: LFMDP), noting a neutral sentiment and a wait-and-see approach. It highlights an exceptional 12.0:1 risk-reward setup targeting a 3.6% gain, with specific trading strategies for position trading, …

LifeMD Reports Second Quarter 2026 Results, Reaches Branded GLP-1 Transition Milestone and Raises Full-Year Guidance

LifeMD, Inc. announced its Q2 2026 financial results, reporting revenues of $47.3 million and a sequential improvement in adjusted EBITDA loss to $3.5 million. The company is transitioning its weight management program to branded GLP-1 therapies, which now account for 95% of new patients, …

LifeMD (NASDAQ:LFMD) Issues Quarterly Earnings Results, Misses Expectations By $0.01 EPS

LifeMD (NASDAQ:LFMD) reported its quarterly earnings, missing analyst expectations with an adjusted EPS of negative $0.16 against a consensus of negative $0.15, and revenue of $47.28 million, falling short of the $49.16 million estimate. The telehealth company also reduced its full-year 2026 guidance due …

LifeMD (NASDAQ:LFMD) Shares Slide After Q2 Revenue and EPS Miss

LifeMD (NASDAQ:LFMD) reported disappointing Q2 2026 results, missing both revenue and non-GAAP EPS consensus estimates. The virtual care and pharmacy services company posted revenue of $47.3 million against a $50.1 million consensus, and a non-GAAP loss per share of $0.16 compared to an expected …

LifeMD (NASDAQ: LFMD) posts Q2 $47.3M revenue, cuts 2026 guidance

LifeMD reported Q2 2026 telehealth revenue of $47.3 million, a 4% year-over-year decrease, though within guidance, as it transitions weight-management patients to branded GLP-1 therapies and longer subscriptions. The company increased active subscribers by 20% to approximately 356,000, and gross margin expanded to 89%. …

LifeMD earnings missed by $0.06, revenue fell short of estimates

LifeMD Q2 Earnings Call Highlights

LifeMD Q2 Results: Revenue falls 3%, adjusted EBITDA loss widens

LifeMD reported a 3% year-over-year revenue decline to $47.3 million in Q2 2026, while its adjusted EBITDA swung to a $3.5 million loss, primarily due to higher customer acquisition costs and a strategic shift to branded GLP-1 therapies. Despite the revenue dip, gross margin …

Earnings call transcript: LifeMD posts Q2 revenue miss, shares sink in after-hours

LifeMD (LFMD) reported a Q2 revenue miss of $47.3 million against an analyst forecast of $49.15 million, alongside an adjusted EBITDA loss and a lowered full-year 2026 outlook, causing shares to drop over 17% in after-hours trading. Despite the financial setbacks, the company highlighted …

LifeMD, Inc. (LFMD) Reports Q2 Loss, Lags Revenue Estimates

LifeMD, Inc. (LFMD) reported a Q2 loss of $0.16 per share, which was an earnings surprise of +20.00% compared to the Zacks Consensus Estimate of a $0.2 loss. However, the company missed revenue estimates, posting $47.28 million against an estimated $49.10 million. Despite outperforming …

LifeMD Q2 2026 slides tout AI platform, results miss targets

LifeMD presented an investor overview in August 2026, highlighting its AI-enabled virtual care platform and growth strategy, despite second-quarter results missing Wall Street expectations. The company's shares fell significantly following the earnings release, nearing its 52-week low. The presentation emphasized LifeMD's transformation into a …

LifeMD (NASDAQ: LFMD) posts $15.96M loss but holds $25.1M cash and $30M credit line

LifeMD, Inc. reported a Q2 2026 net loss of $15.96 million from continuing operations, despite revenues of $47.3 million, a slight decrease from the prior year. The company maintains a strong liquidity position with $25.1 million in cash, no outstanding debt, and an undrawn …

LifeMD (LFMD) Earnings Date and Reports 2026

Earnings To Watch: LifeMD Inc (LFMD) Q2 2026 -- GF Value Sees 92% Upside

LifeMD Inc expected to post a loss of 15 cents a share - Earnings Preview

LifeMD Inc is projected to report a loss of 15 cents per share, according to this earnings preview. The article indicates that this financial expectation comes from Refinitiv. Full details are available to TradingView subscribers.

LifeMD Inc (LFMD) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of LifeMD Inc (LFMD), noting its current valuation score of 9.86 and its rank within the Healthcare Equipment & Supplies industry. It details the company's current P/E ratio, comparing it to recent highs and lows. The article also …